Live Breaking News & Updates on Yakun Wang

Stay updated with breaking news from Yakun wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies. ....

United States , Chunlei Li , Valerie Malyvanh Jansen , Yakun Wang , Elevation Oncology Inc , Corporate Communications Investor Relations , American Society Of Clinical Oncology , Prnewswire Elevation Oncology Inc , Exchange Commission , Group Limited , Drug Administration , American Society , Clinical Oncology , Chief Medical Officer , Elevation Oncology , Chief Scientific Officer , Poster Discussion , Molecularly Targeted Agents , Session Date , Discussion Date , Investigational New Drug , Private Securities Litigation Reform Act , Oncology Investor , Corporate Communications ,

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies. ....

United States , Valerie Malyvanh Jansen , Yakun Wang , Corporate Communications Investor Relations , Elevation Oncology Inc , Group Limited , Drug Administration , American Society Of Clinical Oncology , Prnewswire Elevation Oncology Inc , Exchange Commission , American Society , Clinical Oncology , Elevation Oncology , Chief Medical Officer , Poster Discussion , Molecularly Targeted Agents , Session Date , Discussion Date , Investigational New Drug , Private Securities Litigation Reform Act , Oncology Investor , Corporate Communications ,

QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

/PRNewswire/ QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered. ....

Xiangdong Qu , Jian Zhang , Lin Shen , San Francisco , United States , Yuping Sun , Viva Bio , Xiaohua Chen , Tao Yu , Yanqiao Zhang , Jie Hou , Li Wei , Yusheng Wang , Qin Yu , Jifang Gong , Yakun Wang , Shanghai Pudong Kechuang Group , Qurebio Ltd , Bocom Industrial Investment Hangzhou Equity Partnership , Shenzhen Capital Group , Suzhou Oriza Holdings , Hengrui Pharmaceuticals , Clinical Data , Cancers Symposium , Meeting Abstracts , Viva Bio Innovator ,